Potassium-competitive acid blockers for Helicobacter pylori eradication in pediatrics: a narrative review of pharmacologic rationale, clinical evidence, and practical considerations
Abstract
Helicobacter pylori ( H. pylori ) infection remains highly prevalent worldwide and is strongly associated with chronic gastritis, peptic ulcer disease, and an elevated risk of gastric cancer. In pediatric clinical practice, eradication therapy is challenged by rising antibiotic resistance, inadequate acid suppression, and poor adherence to complex multidrug regimens. Potassium-competitive acid blockers (P-CABs) represent a newer class of antisecretory agents that competitively and reversibly inhibit gastric H + /K + -ATPase, resulting in a more rapid onset and more sustained control of intragastric pH compared with conventional proton pump inhibitors (PPIs). P-CABs offer greater flexibility in dosing timing relative to meals in children, with substantial potential to simplify treatment regimens and improve H. pylori eradication rates in the pediatric population. This narrative review summarizes the pharmacologic rationale for using P-CABs in pediatric H. pylori eradication, synthesizes current clinical evidence—derived mainly from Japanese observational studies of vonoprazan (VPZ)—and discusses key issues regarding resistance, tolerability, and practical clinical application. Published pediatric studies, predominantly involving adolescents and older pediatric cohorts, suggest that VPZ-based regimens may achieve favorable eradication rates, while short-term tolerability appears broadly similar to that of PPI-based therapies in the available comparative data. However, the…
Read the paper
Related studies
- Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2018
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
- Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants
- Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
- Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.